EyePoint, Inc. (EYPT) Stock Price, Financials & Summary

Price chart

Sep 8Sep 11Sep 16Sep 21Sep 24Sep 29Oct 2Oct 7

Key dataOct 7, 2026

Open$3.15

From 52W high−82.05%

Volume2.02M

Market cap$291.69M

P/E (TTM)—

P/S (TTM)104.6x

Div yield—

Key dataOct 7, 2026

Open

$3.15

From 52W high

−82.05%

Volume

2.02M

Market cap

$291.69M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.5x

P/E (TTM)

—

RSI (14)

33.6

MomentumView details →

1D Return

+6.73%

YTD Return

−81.53%

SummaryUpdated Jun 1, 2026

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) is a specialized pharmaceutical company founded in 1987 and headquartered in Watertown, Massachusetts. Originally incorporated as pSivida Corp, the company rebranded to EyePoint Pharmaceuticals in March 2018 to better reflect its focus on ophthalmic treatments. The company has evolved from a diversified pharmaceutical entity into a clinical-stage biopharmaceutical company dedicated exclusively to developing and commercializing innovative treatments for serious eye diseases. EyePoint operates through strategic partnerships across the United States, China, and the United Kingdom, leveraging its proprietary sustained-release drug delivery technology to address unmet medical needs in ophthalmology.

Ask drillr about EyePoint, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.5x

EV/Sales

47.9x

P/S (TTM)

104.6x

P/B (TTM)

1.8x

ProfitabilityView details →

Gross Margin

41.77%

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−184.27%

ROA (TTM)

−134.38%

Asset Turnover

0.01x

GrowthView details →

Revenue YoY

−94.63%

EPS YoY

−39.55%

FCF YoY

−39.81%

Revenue CAGR 3Y

−8.83%

EPS CAGR 3Y

−36.64%

EBITDA YoY

−69.91%

MomentumView details →

1D Return

+6.73%

YTD Return

−81.53%

1Y Return

−75.68%

RSI (14)

33.6

vs 50D SMA

−47.94%

vs 200D SMA

−72.63%

Capital & dividendView details →

Debt/Equity

0.13x

Current Ratio

4.50x

Quick Ratio

4.46x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.09

EPS Surprise

−7.92%

Beats (12Q)

4/12

Next Q EPS Est

−$0.82

Avg Surprise (4Q)

−11.87%

Rev Surprise

12.36%

Financials snapshotView financials →

Revenue (TTM)

2.79M

Net Income (TTM)

−306.64M

Op. CF (TTM)

−267.30M

Next earningsNov 4, 2026 →

Latest newsMore news →

EyePoint, Inc. granted non-statutory stock options to a new employee as an inducement award outside its 2023 Long-Term Incentive Plan under NASDAQ Listing Rule 5635(c)(4).21d ago

Kessler Topaz Meltzer & Check LLP launched an investigation into EyePoint, Inc. for potential federal securities law violations on behalf of investors who suffered significant losses.40d ago

Similar companies

Abeona Therapeutics Inc.ABEO BioAge Labs, Inc.BIOA Larimar Therapeutics, Inc.LRMR Fulcrum Therapeutics, Inc.FULC Rocket Pharmaceuticals, Inc.RCKT Surrozen, Inc.SRZN Find similar companies →

Latest newsMore news →

EyePoint, Inc. granted non-statutory stock options to a new employee as an inducement award outside its 2023 Long-Term Incentive Plan under NASDAQ Listing Rule 5635(c)(4).21d ago Kessler Topaz Meltzer & Check LLP launched an investigation into EyePoint, Inc. for potential federal securities law violations on behalf of investors who suffered significant losses.40d ago